Gyre Therapeutics Inc

NASDAQ:GYRE  
7.74
-0.54 (-6.52%)
5:16:30 PM EDT: $7.96 +0.22 (+2.84%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)657.16M
Current PE75.23
Forward PE 45.53
2yr Forward PE 193.5
See more stats
Estimates Current Quarter
Revenue$33.79 Million
Adjusted EPS$0.07
See more estimates
10-Day MA$7.91
50-Day MA$7.57
200-Day MA$9.71
See more pivots

Gyre Therapeutics Inc Stock, NASDAQ:GYRE

12770 High Bluff Drive, Suite 150, San Diego, California 92130
United States of America
Phone: +1.619.949.3681
Number of Employees: 5

Description

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.